8-K: Lifeward Appoints Mark Grant as New CEO, Aiming for Growth and Profitability

Lifeward Ltd. has appointed Mark Grant as its new President and CEO, effective June 2, 2025, to drive growth and profitability.

Summary

• Lifeward Ltd. announced the appointment of Mark Grant as the new President and Chief Executive Officer, effective June 2, 2025.
• Larry Jasinski, the current CEO, will serve as Co-CEO with Mr. Grant until June 30, 2025, and then in an advisory role until the end of 2025.
• Mr. Grant brings 30 years of commercial leadership experience in healthcare and medical technology.
• He previously served as President of Americas & Chief Commercial Officer of International Medical Robotics Academy and held various positions at Medtronic, including Vice President, Americas Region, where he led a $1.5 billion region.
• Mr. Grant's employment agreement includes an annual base salary of $435,000 and a potential annual performance bonus of up to 70% of his base salary.
• He will also receive an inducement grant of options to purchase 400,000 of the Company's Ordinary Shares, vesting in four equal annual installments.
• The company aims to leverage its strengths to achieve balanced and sustainable growth and work strategically toward profitability.
• Lifeward's portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced CEO, a smooth leadership transition plan, and a focus on growth and profitability. The company's existing product portfolio and Medicare payment for ReWalk further contribute to the positive outlook.

Positives

• Mark Grant brings 30 years of commercial leadership experience to Lifeward.
• The leadership transition is structured to be smooth, with Larry Jasinski assisting until the end of 2025.
• The company is focused on achieving balanced and sustainable growth and profitability.
• Lifeward has a robust portfolio of life-changing solutions, including the ReWalk Exoskeleton.
• The company has achieved Medicare payment for the ReWalk exoskeleton.

Risks

• The company's future performance is subject to uncertainties, risks, and changes in circumstances.
• Factors that could affect results include the acceptance of the ReWalk 7 Personal Exoskeleton, clinical trial outcomes, and regulatory approvals.
• The company's ability to have sufficient funds to meet future capital requirements is a risk.
• Maintaining market acceptance of its products and achieving reimbursement from third-party payors are also risks.
• The company's limited operating history and ability to leverage its infrastructure pose challenges.

Future Outlook

Lifeward aims to leverage its strengths to achieve balanced and sustainable growth and work strategically toward profitability. The company is focused on driving innovations that change the lives of individuals with physical limitations or disabilities.

Management Comments

• 'Mark brings 30 years of combined experience in commercial leadership, channel development and strategic solutions, and is the perfect choice to lead Lifeward in its next stage of growth,' said Joseph Turk, Chairman of the Lifeward Board of Directors.
• Mr. Grant stated he is 'thrilled and honored to be joining the Lifeward team at such an exciting time in its history' and looks forward to helping Lifeward leverage its many strengths to achieve balanced and sustainable growth.

Industry Context

The appointment of Mark Grant reflects Lifeward's strategic focus on strengthening its commercial leadership and driving growth in the medical technology sector, particularly in the area of physical rehabilitation and recovery. The company's focus on innovative solutions like the ReWalk Exoskeleton aligns with the increasing demand for advanced medical devices that improve the quality of life for individuals with physical limitations.

Comparison to Industry Standards

• Medtronic, where Mark Grant previously held a leadership role, is a global leader in healthcare technology, indicating that Mr. Grant has experience in a large, successful organization.
• The ReWalk Exoskeleton competes with other exoskeletons from companies like Ekso Bionics and Cyberdyne, and achieving Medicare payment is a significant milestone compared to these competitors.
• Lifeward's focus on ethical surgical training solutions through IMRA Surgical aligns with the industry's growing emphasis on improving surgical outcomes and patient safety.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CEO with extensive experience as a positive step towards achieving growth and profitability.
• Employees may experience changes in leadership and strategic direction under the new CEO.
• Customers and patients may benefit from the company's focus on innovation and life-changing solutions.
• The patient advocacy community is expected to continue working with Lifeward to improve the quality of life for patients.

Next Steps

• Mark Grant will assume the role of President and CEO on June 2, 2025.
• Larry Jasinski will serve as Co-CEO until June 30, 2025, and then transition to an advisory role.
• The Company will file the Employment Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• The inducement grant of options will be made on the date Mr. Grant joins the Company.

Key Dates

Keywords

Lifeward, Mark Grant, CEO, Appointment, ReWalk, Exoskeleton, Medical Technology, Leadership, Growth, Profitability